A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers

Inclusion Criteria: * Males and females between 18 and 45 years of age. * Body weight range ≥ 50 kg ≤ 100 kg and BMI within the range 18.5 - 29.9 kg/m2. * Healthy as determined by a responsible and experienced physician, based on a medial evaluation. * Male and female subjects of childbearing potential agree to adhere to the contraception requirements. * Capable of giving written informed consent. Exclusion Criteria: * History of sensitivity to migalastat HCl or related iminosugars (eg, miglitol, miglustat), or other significant drug allergy. * Past medical history, or physical examination findings, of clinically significant abnormalities that may put the subject at risk or interfere with outcome variables. * Positive pre-study drug/alcohol screen. * Pregnant or lactating females. * The subject has participated in a clinical trial and has received an investigational product within 60 days prior to the first dosing day in the current study.